Eton Pharmaceuticals, Inc. Deferred Tax Assets, Operating Loss Carryforwards
Eton Pharmaceuticals, Inc. (ETON) had Deferred Tax Assets, Operating Loss Carryforwards of $14.09 million as of 2025-12-31, per its 10-K filed 2026-03-19.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsOperatingLossCarryforwards · last filed 2026-03-19
- 2025-12-31: Deferred Tax Assets, Operating Loss Carryforwards $14.09M.
- 2024-12-31: Deferred Tax Assets, Operating Loss Carryforwards $14.14M.
- 2023-12-31: Deferred Tax Assets, Operating Loss Carryforwards $15.45M.
- 2022-12-31: Deferred Tax Assets, Operating Loss Carryforwards $17.18M.
| Period end | Deferred Tax Assets, Operating Loss Carryforwards |
|---|---|
| 2025-12-31 | $14.09M 10-K · filed 2026-03-19 |
| 2024-12-31 | $14.14M 10-K · filed 2026-03-19 |
| 2023-12-31 | $15.45M 10-K · filed 2025-03-18 |
| 2022-12-31 | $17.18M 10-K · filed 2024-03-14 |
| 2021-12-31 | $15.87M 10-K · filed 2023-03-16 |
| 2020-12-31 | $16.25M 10-K · filed 2022-03-16 |
| 2019-12-31 | $8.88M 10-K · filed 2021-03-16 |
| 2018-12-31 | $3.97M 10-K · filed 2020-03-05 |
| 2017-12-31 | $1.61M 10-K · filed 2019-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |